Actively Recruiting
Evaluating 68Ga-HA-DOTATATE PETCT Imaging for Diagnosis and Monitoring of Neuroendocrine Tumors in Adults
Led by Alberta Health services · Updated on 2023-01-05
500
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of 68Ga-HA-DOTATATE PETCT imaging to diagnose somatostatin-positive neuroendocrine tumors compared to conventional imaging methods such as CT, MRI, 111 In-pentetreotide scans, and 18F-FDG PETCT. The study aims to assess the usefulness of 68Ga-HA-DOTATATE in initial diagnosis, surveillance of completely removed tumors, and localization of functioning tumors like insulinoma and gastrinoma. Participants will receive an intravenous injection of 100-250 MBq of 68Ga-HA-DOTATATE. Imaging starts 45-90 minutes after the injection, followed by a CT scan for localization without moving the patient. The 68Ga-HA-DOTATATE PETCT results will be compared to any prior imaging and pathology reports to evaluate its diagnostic utility. During the study, participants will undergo the PETCT imaging procedure and provide informed consent. The research team will monitor the imaging results over five years to assess the diagnostic value of 68Ga-HA-DOTATATE PETCT. Participants are expected to comply with study instructions and attend scheduled imaging sessions as part of this observational study.
CONDITIONS
Brief Title
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
